Education
About Us
Working with TipRanks
Follow Us
Globus Medical (GMED)
NYSE:GMED
GMED Analyst Ratings
Moderate Buy
8 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GMED Stock 12 Month Forecast
Average Price Target
$83.00
▲(34.94% Upside)
| Highest Price Target$106.00 | Average Price Target$83.00 | Lowest Price Target$65.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Citizens JMP
―
Hold
―
Reiterated
08/20/25
Morgan Stanley
$68→$70
Buy
13.80%
Upside
Reiterated
08/14/25
TR | OpenAI - 4o
$67→$69
Buy
12.18%
Upside
Reiterated
08/14/25
Truist Financial
$65
Hold
5.67%
Upside
Reiterated
08/11/25
Barclays
$103→$106
Buy
72.33%
Upside
Reiterated
08/08/25
Roth MKM
$105
Buy
70.70%
Upside
Reiterated
08/08/25
Bank of America Securities
$65
Hold
5.67%
Upside
Reiterated
08/08/25
Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), Globus Medical (NYSE: GMED) and BioMarin Pharmaceutical (NASDAQ: BMRN)We update our model for Q2. Early Nevro P&L does not look that bad; accretive in yr 2 Nevro’s operating income in Q2 on its $95m of revenue was -$5m or -5%. Opex was $68m or 71%. While well below GMED’s profitability, Nevro’s -5% OM is well ahead of where it was as a stand-alone company in Q2 2024 (-24%). GMED reiterated that it expects the Nevro deal to be accretive to EPS in year 2 post deal. GMED said that the amount of accretion will be determined by how much of Nevro sales are lost. Nevro sales outperformance opportunity for upside Nevro contributed $95m of revenue in the quarter which was better than our $88m estimate and above the $350m annualized run rate GMED had expected. We continue to model $150m of Nevro sales in 2H ($300m annualized run rate) but think there could be upside given Q2 results.
Wells Fargo
$76→$66
Buy
7.30%
Upside
Reiterated
08/08/25
Piper Sandler
$80
Buy
30.06%
Upside
Reiterated
08/08/25
Canaccord Genuity
$90
Buy
46.32%
Upside
Reiterated
08/07/25
RBC Capital
$95
Buy
54.45%
Upside
Reiterated
08/07/25
Jefferies
$90→$88
Buy
43.07%
Upside
Reiterated
07/22/25
BTIG
―
Hold
―
Reiterated
07/21/25
Oppenheimer
$90→$78
Hold
26.81%
Upside
Reiterated
05/09/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Citizens JMP
―
Hold
―
Reiterated
08/20/25
Morgan Stanley
$68→$70
Buy
13.80%
Upside
Reiterated
08/14/25
TR | OpenAI - 4o
$67→$69
Buy
12.18%
Upside
Reiterated
08/14/25
Truist Financial
$65
Hold
5.67%
Upside
Reiterated
08/11/25
Barclays
$103→$106
Buy
72.33%
Upside
Reiterated
08/08/25
Roth MKM
$105
Buy
70.70%
Upside
Reiterated
08/08/25
Bank of America Securities
$65
Hold
5.67%
Upside
Reiterated
08/08/25
Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), Globus Medical (NYSE: GMED) and BioMarin Pharmaceutical (NASDAQ: BMRN)We update our model for Q2. Early Nevro P&L does not look that bad; accretive in yr 2 Nevro’s operating income in Q2 on its $95m of revenue was -$5m or -5%. Opex was $68m or 71%. While well below GMED’s profitability, Nevro’s -5% OM is well ahead of where it was as a stand-alone company in Q2 2024 (-24%). GMED reiterated that it expects the Nevro deal to be accretive to EPS in year 2 post deal. GMED said that the amount of accretion will be determined by how much of Nevro sales are lost. Nevro sales outperformance opportunity for upside Nevro contributed $95m of revenue in the quarter which was better than our $88m estimate and above the $350m annualized run rate GMED had expected. We continue to model $150m of Nevro sales in 2H ($300m annualized run rate) but think there could be upside given Q2 results.
Wells Fargo
$76→$66
Buy
7.30%
Upside
Reiterated
08/08/25
Piper Sandler
$80
Buy
30.06%
Upside
Reiterated
08/08/25
Canaccord Genuity
$90
Buy
46.32%
Upside
Reiterated
08/07/25
RBC Capital
$95
Buy
54.45%
Upside
Reiterated
08/07/25
Jefferies
$90→$88
Buy
43.07%
Upside
Reiterated
07/22/25
BTIG
―
Hold
―
Reiterated
07/21/25
Oppenheimer
$90→$78
Hold
26.81%
Upside
Reiterated
05/09/25
Best Analysts Covering Globus Medical
1 Month
xxx
Success Rate
14/23 ratings generated profit
Average Return
+2.47%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.87% of your transactions generating a profit, with an average return of +2.47% per trade.
3 Months
xxx
Success Rate
15/23 ratings generated profit
Average Return
+2.94%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 65.22% of your transactions generating a profit, with an average return of +2.94% per trade.
1 Year
Success Rate
22/34 ratings generated profit
Average Return
+11.93%
reiterated a buy rating 22 days ago
Copying Matt Miksic's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +11.93% per trade.
2 Years
xxx
Success Rate
27/34 ratings generated profit
Average Return
+21.27%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 79.41% of your transactions generating a profit, with an average return of +21.27% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GMED Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
1
4
6
11
12
Buy
29
19
13
11
8
Hold
11
12
9
16
13
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
41
35
28
38
33
Each month's total comprises the sum of three months' worth of ratings.
GMED Financial Forecast
GMED Stock Forecast FAQ
What is GMED’s average 12-month price target, according to analysts?
Based on analyst ratings, Globus Medical’s 12-month average price target is 83.00.
What is GMED’s upside potential, based on the analysts’ average price target?
Globus Medical has 34.94% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GMED a Buy, Sell or Hold?
Globus Medical has a consensus rating of Moderate Buy which is based on 8 buy ratings, 5 hold ratings and 0 sell ratings.
What is Globus Medical’s price target?
The average price target for Globus Medical is 83.00. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $106.00 ,the lowest forecast is $65.00. The average price target represents 34.94% Increase from the current price of $61.51.
The highest analyst price target is $106.00 ,the lowest forecast is $65.00. The average price target represents 34.94% Increase from the current price of $61.51.
What do analysts say about Globus Medical?
Globus Medical’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of GMED?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.